TOLREMO Therapeutics AG
2 known investors
Find your way into TOLREMO Therapeutics AG
TOLREMO therapeutics develops small molecule inhibitors targeting transcriptional resistance mechanisms in cancer, with a lead clinical candidate TT125-802 designed for solid tumors and hematological malignancies as both monotherapy and combination treatment.
Investors · 2
Competitors · 2
by search overlapBioworld7 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Terremotobio5 shared keywordsTerremoto Biosciences is a clinical-stage biotech developing precision therapies for oncology and genetic diseases using lysine-targeted covalent chemistry. It pursues both best-in-class treatments against known drug targets and first-in-class medicines against previously undruggable targets.
Companies competing with TOLREMO Therapeutics AG for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does TOLREMO Therapeutics AG do?
- TOLREMO therapeutics develops small molecule inhibitors targeting transcriptional resistance mechanisms in cancer, with a lead clinical candidate TT125-802 designed for solid tumors and hematological malignancies as both monotherapy and combination treatment.
- Who are TOLREMO Therapeutics AG's investors?
- TOLREMO Therapeutics AG's investors include BioMedPartners, redalpine.